Trial to raise awareness of gender and CVD

More women than men die of cardiovascular disease (CVD) every year, yet females receive only 33% of angioplasties, stents and bypass surgeries; 28% of implantable defibrillators, and 36% of open heart surgeries.

Photo: Trial to raise awareness of gender and CVD

Looking at this situation, Abbott, which produces the Xience V Everolimus Eluting Coronary Stent System, is involved in a clinical trial - in Europe, Asia-Pacific, Canada and Latin America – to study the stent’s safety and effectiveness in women patients who have untreated coronary artery lesions.

The first patient to enrol in the trial, called Xience V Spirit Women, has been operated on in Argentina, by Liliana Grinfeld MD, at the Italian Hospital in Buenos Aires, Argentina, who reported that the stent system had performed well, and that the patient will be checked for up to five years.

Abbott reports that the trial will focus on ‘…specific aspects of women’s health in relation to coronary artery disease, such as general awareness about the disease, symptoms at time of presentation, referral patterns, and hormonal menopausal status.’

The trial’s principal investigator, Marie-Claude Morice MD, at the Jaques Cartier Institute, in Massy, France, commented that it is ‘tragic’ that women amount to just 25% of participants in all heart-related research studies, and added that the trial had the potential to enhance access to CVD therapy by increasing their and their physicians’ awareness.

01.09.2007

Read all latest stories

Related articles

Photo

News • Minimally invasive cardiology

TAVI: viable alternative to open heart surgery in aortic stenosis

Transcatheter Aortic Valve Implantation (TAVI) is a less invasive procedure that is just as effective as open-heart surgery in treating severe symptomatic aortic stenosis, a new study shows.

Photo

Article • Risk reduction, rehabilitation

The role of AI in preventive cardiology

Artificial Intelligence and Big Data in cardiovascular risk reduction and cardiac rehabilitation are offering new opportunities for increased diagnostic accuracy and more personalised exercise…

Photo

Article • Preventive cardiology

AI to measure coronary plaque in six seconds

Coronary computed tomography angiography (CCTA) is a non-invasive imaging test which can be used to evaluate coronary artery stenosis and measure plaques. Current plaque analysis is time-consuming…

Related products

Canon – Alphenix Core

Single Plane

Canon – Alphenix Core

Canon Medical Systems Europe B.V.
Ziehm – Vision R

Surgical II-C-Arms

Ziehm – Vision R

Ziehm Imaging GmbH
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Canon – Alphenix Biplane High Definition Detector

Bi-Plane

Canon – Alphenix Biplane High Definition Detector

Canon Medical Systems Europe B.V.
Canon – Alphenix Core+

Single Plane

Canon – Alphenix Core+

Canon Medical Systems Europe B.V.
Subscribe to Newsletter